SCHEMBL31728714

SCHEMBL31728714

COc1cc(O)c(-c2ccc(F)c(Cl)c2F)c2ncnc(N)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 1/20 0.39
▸ KDR P35968 10/20 0.36
▸ RET P07949 2/20 0.36
▸ KIF5B P33176 2/20 0.36
▸ PDE5A O76074 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ EPHB4 P54760 9/20 0.36
▸ ABL1 P00519 8/20 0.36
▸ EGFR P00533 8/20 0.36
▸ HCK P08631 8/20 0.36
▸ SRC P12931 8/20 0.36
▸ PIK3CB P42338 8/20 0.36
▸ MTOR P42345 8/20 0.36
▸ PIK3CG P48736 8/20 0.36
▸ PRKDC P78527 8/20 0.36
▸ PI4KB Q9UBF8 8/20 0.36
▸ PIK3CD O00329 7/20 0.36
▸ PIK3CA P42336 7/20 0.36
▸ EIF2AK3 Q9NZJ5 2/20 0.35
▸ LRRK2 Q5S007 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31729157 0.90 PDE5A (0.39) FYNKDRPDE5AEPHB4ABL1
SCHEMBL31728941 0.84 EIF2AK3 (0.39) KDRPDE5AGSK3BEPHB4ABL1
SCHEMBL31728213 0.82 EIF2AK3 (0.38) FYNKDRPDE5AEPHB4ABL1
SCHEMBL31728453 0.82 CLK1 (0.38) KDREPHB4ABL1EGFRHCK
SCHEMBL31728961 0.81 EGFR (0.38) KDREPHB4ABL1EGFRHCK
SCHEMBL31728591 0.80 EIF2AK3 (0.39) FYNKDRPDE5AGSK3BEPHB4
SCHEMBL31728406 0.79 PIK3CD (0.31) KDREPHB4ABL1EGFRHCK
SCHEMBL31729134 0.77 GSK3B (0.41) FYNKDRPDE5AGSK3BEPHB4
SCHEMBL31728133 0.76 CLK1 (0.36) FYNKDRGSK3BEPHB4ABL1
SCHEMBL31729163 0.75 CLK1 (0.37) KDRRETGSK3BEPHB4ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback